azacitidine has been researched along with Neutropenia in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 2 (5.00) | 18.2507 |
| 2000's | 4 (10.00) | 29.6817 |
| 2010's | 24 (60.00) | 24.3611 |
| 2020's | 9 (22.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brasacchio, D; DiCorleto, C; Gamgee, J; Gasiorowski, R; Gregory, GP; Gruber, E; Hawkes, EA; Hogg, SJ; Jia, W; Jong, I; Kailainathan, G; Kats, LM; Kumar, B; Levy, S; Lewis, A; Luong, Q; Maher, B; Opat, S; Polekhina, G; Reynolds, J; Sabouri-Thompson, Z; Shortt, J; Skinner, H; So, J; Uhe, M; Vervoort, S; Waltham, M; Wong, J | 1 |
| Sekeres, MA; Taylor, J | 1 |
| Bajel, A; Borate, U; Brunner, AM; Cheng, WH; Filshie, R; Garcia, JS; Garcia-Manero, G; Harb, JG; Hoffman, D; Krishnadasan, R; Naqvi, K; Odenike, O; Pollyea, DA; Potluri, J; Roncolato, F; Watson, AM; Zeidan, AM; Zha, J; Zhou, Y | 1 |
| Bai, LY; Chen, TT; Chou, CH; Ho, MW; Lien, MY; Lin, CC; Wang, ST; Yeh, SP | 1 |
| Chang, XL; Guo, YX; Hu, RH; Hui, WH; Lan, XX; Su, L; Sun, WL; Zhang, Y; Zhao, H | 1 |
| Fujita, J; Hirose, Y; Kamimura, R; Kiyohara, E; Nagate, Y; Nakaya, A; Nojima, S; Shibayama, H | 1 |
| Bossi, P; Chen, P; Haddad, RI; Hansen, AR; Hsieh, CY; Licitra, LF; Mesia, R; Miller, J; Siu, LL; Tan, EH | 1 |
| Cardamone, L; Paul, E; Rogers, B; Shaw, B; Shepherd, S; Shortt, J; Tey, A | 1 |
| Bowen, D; Cargo, C; Culligan, D; Enright, H; Green, S; Ingram, W; Jones, GL; Kell, J; Killick, SB; Krishnamurthy, P; Kulasekararaj, A; Mills, J; Mufti, G; Payne, EM; Quek, L; Raghavan, M; Stanworth, SJ; Sternberg, A; Wiseman, DH | 1 |
| Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J | 1 |
| Hofmann, WK; Nolte, F; Platzbecker, U; Radsak, M; Schmidt, CS | 1 |
| Abboud, CN; Ali, AM; Cashen, AF; DiPersio, JF; Fehniger, TA; Gao, F; Ghobadi, A; Jacoby, MA; Oh, ST; Pusic, I; Romee, R; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wartman, LD; Weisel, D; Welch, JS; Westervelt, P | 1 |
| Bang, SM; Cheong, JW; Kim, BS; Kim, CS; Kim, HJ; Kim, I; Kim, SY; Kim, YK; Lee, HG; Lee, JH; Lee, JO; Lee, YG; Min, YH; Mun, YC; Park, J; Park, S; Park, Y; Seong, CM; Yi, HG; Yoon, SS | 1 |
| Absalon, M; Blum, W; Broun, R; Davies, SM; Garzon, R; Marcucci, G; McMasters, R; Mo, J; Moscow, JA; O'Brien, M; Perentesis, JP; Phillips, CL; Schwind, S; Smolarek, T | 1 |
| Douvali, E; Kotsianidis, I; Papadopoulos, V; Papoutselis, M; Spanoudakis, E; Tsatalas, C; Vassilakopoulos, TP | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Bochtler, T; Dietrich, S; Dreger, P; Ho, AD; Krämer, A; Luft, T; Radujkovic, A; Schöning, T | 1 |
| Bassett, RL; Desai, JR; Hwu, WJ; Ilagan, JL; Issa, JP; Jelinek, J; Papadopoulos, NE; Plimack, ER; Sharma, P; Vence, LM | 1 |
| De Castro, CM; Griffin, PT; Komrokji, RS; Lancet, JE; List, AF; Melchert, M; Rizzieri, DA | 1 |
| Bernig, T; Catala, A; Cseh, AM; De Moerloose, B; Flotho, C; Frühwald, MC; Furlan, I; Gruhn, B; Hasle, H; Kulozik, AE; Lauten, M; Metzler, M; Niemeyer, CM; Olcay, L; Smith, OP; Strahm, B; Suttorp, M; van den Heuvel-Eibrink, MM; Yoshimi, A | 1 |
| Arnan, M; Duarte, RF; Pomares, H; Sánchez-Ortega, I; Sureda, A | 1 |
| Lu, SY; Wang, C; Wang, Z; Zhao, XH; Zhou, ZH | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Andritsos, L; Baiocchi, R; Benson, DM; Blum, KA; Byrd, JC; Chan, KK; Chen, P; Devine, SM; Flynn, J; Grever, MR; Jones, J; Liu, Z; Lucas, DM; Marcucci, G; Plass, C; Xie, Z | 1 |
| Aggerholm, A; Antunovic, P; Astermark, J; Bernell, P; Engström, LM; Grövdal, M; Hellström-Lindberg, E; Hokland, P; Holm, MS; Jacobsen, SE; Karimi, M; Khan, R; Kjeldsen, L; Linder, O; Nilsson, L; Oberg, G; Olsson, A; Porwit, A; Tangen, JM; Wallvik, J | 1 |
| Choi, MY; Choi, Y; Joo, YD; Kim, DY; Kim, SD; Kim, SH; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN | 1 |
| Font, P | 1 |
| Cogle, C; Garcia-Manero, G; Giordano, H; Gore, SD; Jabbour, E; Kantarjian, H; Laille, E; Macbeth, KJ; Sakoian, S; Shi, T; Skikne, B; Ward, R | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Martínez-Francés, A | 1 |
| Franco Osorio, R; Martínez-Francés, A; Mercadal Vilchez, S; San Miguel Amigo, L | 1 |
| Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S | 1 |
| Daskalakis, M; Engelhardt, M; Guo, Y; Kunzmann, R; Lübbert, M; Wijermans, P | 1 |
| Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T | 1 |
| Cortes, JE; Garcia-Manero, G; Kantarjian, H; Kornblau, S; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Tong, W; Verstovsek, S | 1 |
| Glaubiger, DL; LeVine, AS; Poplack, DG; Reaman, GH; Srinivasan, U | 1 |
| Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Ben-Baruch, N; Cowan, KH; Fine, R; Ford, H; Kelley, JA; Surbone, A; Thomas, RV | 1 |
5 review(s) available for azacitidine and Neutropenia
| Article | Year |
|---|---|
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Erythropoietin; Female; Hematinics; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Thrombocytopenia | 2022 |
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
Topics: Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Infections; Morbidity; Mortality; Myelodysplastic Syndromes; Neutropenia | 2017 |
Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Clinical Trials, Phase III as Topic; Contraindications; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Myelodysplastic Syndromes; Neutropenia; Practice Guidelines as Topic; Prognosis; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2011 |
Adverse effects of azacitidine: onset, duration, and treatment.
Topics: Age of Onset; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Fatigue; Gastrointestinal Diseases; Humans; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neutropenia; Prognosis; Survival Rate | 2011 |
Azacitidine adverse effects in patients with myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Fatigue; Gastrointestinal Diseases; Humans; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neutropenia; Prognosis; Quality-Adjusted Life Years; Survival Rate | 2011 |
20 trial(s) available for azacitidine and Neutropenia
| Article | Year |
|---|---|
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Topics: Azacitidine; Decitabine; Genomics; Humans; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome | 2022 |
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Sulfonamides; Treatment Outcome | 2023 |
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Native Hawaiian or Other Pacific Islander; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; White People | 2019 |
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Placebo Effect; Remission Induction; Thrombocytopenia | 2021 |
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Bone Marrow Examination; Decitabine; Disease-Free Survival; Female; Humans; Infection Control; Kaplan-Meier Estimate; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Research Design; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult | 2013 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; T-Lymphocyte Subsets | 2014 |
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Induction Chemotherapy; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Pilot Projects; Remission Induction; Survival Analysis; Thrombocytopenia | 2015 |
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Polymerase Chain Reaction; Promoter Regions, Genetic; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Appendicitis; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Fluoroquinolones; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Time Factors; Treatment Outcome | 2011 |
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; DNA Methylation; Fatigue; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia | 2011 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).
Topics: Aged; Azacitidine; Cell Proliferation; Clone Cells; Decitabine; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Leukocyte Count; Leukopoiesis; Male; Myelodysplastic Syndromes; Neutropenia; Neutrophils | 2004 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Diseases; Decitabine; Fatigue; Humans; Infections; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Remission Induction; Treatment Failure; Valproic Acid | 2007 |
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; DNA Methylation; Female; Humans; Janus Kinase 2; Male; Middle Aged; Neutropenia; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential; Treatment Outcome | 2008 |
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia | 1997 |
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1990 |
15 other study(ies) available for azacitidine and Neutropenia
| Article | Year |
|---|---|
High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia.
Topics: Antifungal Agents; Azacitidine; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Neutropenia; Retrospective Studies | 2022 |
A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Retrospective Studies | 2023 |
Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm.
Topics: Aged; Aged, 80 and over; Azacitidine; Dendritic Cells; Humans; Male; Myeloproliferative Disorders; Neutropenia; Skin Neoplasms | 2023 |
Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Azacitidine; Disease Susceptibility; Female; Humans; Incidence; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2021 |
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Topics: Adult; Anemia; Antineoplastic Agents; Azacitidine; Blood Transfusion; Decitabine; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia | 2021 |
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Missouri; Mycoses; Myelodysplastic Syndromes; Neutropenia; Opportunistic Infections; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Virus Diseases | 2017 |
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Child; Child, Preschool; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Neoplasm Proteins; Neutropenia; Remission Induction; RNA, Neoplasm; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2013 |
Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Remission Induction; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2013 |
Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Hemorrhage; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Palliative Care; Pneumonia; Retrospective Studies; Survival Analysis | 2014 |
Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Myelodysplastic Syndromes; Neutropenia; Palliative Care; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Neutropenia; Numbers Needed To Treat; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Triazoles | 2016 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimen in the Treatment of Elderly MDS Patients with AML Transformed by Abnormal Proliferation of Bone Marrow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Proliferation; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neutropenia; Quality of Life; Treatment Outcome | 2016 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Disease Susceptibility; Female; Humans; Incidence; Infections; Israel; Leukemia, Myeloid, Acute; Male; Methylation; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia | 2013 |
Phase II study of 5-azacytidine in sarcomas of bone.
Topics: Adolescent; Adult; Azacitidine; Bone Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukocyte Count; Male; Neoplasm Metastasis; Neutropenia; Osteosarcoma; Platelet Count; Sarcoma, Ewing; Thrombocytopenia | 1982 |